DISEASE risk factorsPROGNOSISNIVOLUMABOVERALL survivalIMDC is the most important prognostic score for 1 line mRCC; it might be useful in subsequent lines. 492 pts were analyzed for IMDC changes from baseline to 鈮 2 line nivolumab start. Longer mPFS and mOS were reached by...
The risk group and corresponding estimated median survival in the TKI era will be displayed at the bottom of the calculator. - Use baseline factors at the start date of the current line of systemic therapy, except for the “time from diagnosis to systemic therapy” criterion, which is always...
ToexplorefactorsotherthanIMDC (InternationalmRCCDatabaseConsortium)riskstratifica- tionthatcanindependentlypredicttheoverallmortalityriskinpatientsfollowingcytoreductivenephrectomy,andtocon- structacombinedpredictionmodeltoguidetheindicationselection.Methods:Patient'sdatafromtheInternationalConsorti- ∗基金项目:国家自然...
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214doi:10.1016/j.eururo.2019.10.025Bernard EscudierRobert J. MotzerNizar M. TannirCamillo PortaYoshihiko TomitaMatthew A. MaurerM. Brent McHenryBrian I. Rini...
IMDCNon-small cell lung cancerImmunotherapyNivolumabPrognosticBiomarkerAlthough there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical parameters of IMDC risk ...
subpopulations with different OS (HR 1.88, p=0.046): B/L/N-positive INT OS rates were not different from POOR (p=0.193) and B/L/N-negative INT OS rates were comparable to FAV (p=0.193).Conclusions:B/L/N metastases are independent prognostic factors in mRCC, despite being unaddressed ...
prognostic score was derived based on total risk score from 6 prognostic factors at baseline and month 6 (+/- 2 weeks).#a4 pts had a missing score at baseline.#bIMDC prognostic score was derived based on total risk score from 6 prognostic factors at baseline and month 6 (+/- 2 weeks...